GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma
Status:
Recruiting
Trial end date:
2026-01-15
Target enrollment:
Participant gender:
Summary
The clinical trial is designed to evaluate the safety and efficacy of GEMOX combined with
targeted therapy and immunotherapy for patients with advanced cholangiocarcinoma, and screen
the potential biomarkers
Phase:
N/A
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital